Affimed N.V. – NASDAQ:AFMD

Affimed N.V. stock price today

$0.182
-1.10
-85.93%
Financial Health
0
1
2
3
4
5
6
7
8
9

Affimed N.V. stock price monthly change

-74.95%
month

Affimed N.V. stock price quarterly change

-74.95%
quarter

Affimed N.V. stock price yearly change

+173.19%
year

Affimed N.V. key metrics

Market Cap
17.79M
Enterprise value
N/A
P/E
-1.09
EV/Sales
-2.41
EV/EBITDA
1.34
Price/Sales
2.22
Price/Book
0.49
PEG ratio
-0.27
EPS
-6.22
Revenue
3.92M
EBITDA
-90.21M
Income
-93.13M
Revenue Q/Q
-96.56%
Revenue Y/Y
-89.64%
Profit margin
-186.64%
Oper. margin
-202.75%
Gross margin
0%
EBIT margin
-202.75%
EBITDA margin
-2301.35%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Affimed N.V. stock price history

Affimed N.V. stock forecast

Affimed N.V. financial statements

Affimed N.V. (NASDAQ:AFMD): Profit margin
Jun 2023 1.39M -29.39M -2114.75%
Sep 2023 1.96M -24.35M -1241.34%
Dec 2023 413K -20.20M -4892.25%
Mar 2024 155K -19.17M -12370.97%
Affimed N.V. (NASDAQ:AFMD): Analyst Estimates
Sep 2025 535.16K -11.24M -2101.34%
Dec 2025 6.37M -243.27M -3815.16%
Dec 2025 535.16K -12.35M -2308.74%
Mar 2026 152.96K -12.38M -8094.89%
  • Analysts Price target

  • Financials & Ratios estimates

Affimed N.V. (NASDAQ:AFMD): Debt to assets
Jun 2023 134711000 35.78M 26.56%
Sep 2023 120464000 44.04M 36.56%
Dec 2023 97157000 39.35M 40.5%
Mar 2024 70553000 29.89M 42.37%
Affimed N.V. (NASDAQ:AFMD): Cash Flow
Jun 2023 -33.33M -3K -2.58M
Sep 2023 -18.25M -37.45M -1.61M
Dec 2023 -25.44M 1.40M -1.39M
Mar 2024 -23.81M -1K -417K

Affimed N.V. alternative data

Affimed N.V. (NASDAQ:AFMD): Employee count
Aug 2023 219
Sep 2023 219
Oct 2023 219
Nov 2023 219
Dec 2023 219
Jan 2024 219
Feb 2024 219
Mar 2024 219
Apr 2024 219
May 2024 76
Jun 2024 76
Jul 2024 76

Affimed N.V. other data

48.89% -17.54%
of AFMD is owned by hedge funds
72.03M -7.35M
shares is hold by hedge funds
Insider Compensation
Dr. Adi Hoess (1961) Chief Executive Officer, MD & Member of Management Board
$825,050
Dr. Wolfgang Fischer (1964) MD, Chief Operating Officer & Member of Management Board
$648,730
Dr. Arndt J. G. Schottelius (1966) Chief Scientific Officer
$592,110
Mr. Angus W. Smith (1982) Chief Financial Officer $529,120
Dr. Andreas Harstrick M.D. (1961) Chief Medical Officer
$461,350
Monday, 9 December 2024
globenewswire.com
globenewswire.com
Sunday, 8 December 2024
globenewswire.com
Friday, 6 December 2024
zacks.com
Thursday, 5 December 2024
globenewswire.com
Thursday, 14 November 2024
seekingalpha.com
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Tuesday, 10 September 2024
globenewswire.com
Thursday, 5 September 2024
seekingalpha.com
globenewswire.com
Wednesday, 4 September 2024
seekingalpha.com
zacks.com
Tuesday, 3 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Wednesday, 12 June 2024
seekingalpha.com
globenewswire.com
Wednesday, 5 June 2024
globenewswire.com
Tuesday, 4 June 2024
zacks.com
zacks.com
Saturday, 1 June 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
investorplace.com
Thursday, 23 May 2024
globenewswire.com
Friday, 17 May 2024
investorplace.com
Tuesday, 14 May 2024
globenewswire.com
Wednesday, 24 April 2024
Zacks Investment Research
Wednesday, 17 April 2024
Zacks Investment Research
Thursday, 4 April 2024
Zacks Investment Research
  • What's the price of Affimed N.V. stock today?

    One share of Affimed N.V. stock can currently be purchased for approximately $0.18.

  • When is Affimed N.V.'s next earnings date?

    Unfortunately, Affimed N.V.'s (AFMD) next earnings date is currently unknown.

  • Does Affimed N.V. pay dividends?

    No, Affimed N.V. does not pay dividends.

  • How much money does Affimed N.V. make?

    Affimed N.V. has a market capitalization of 17.79M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 79.99% to 8.28M US dollars.

  • What is Affimed N.V.'s stock symbol?

    Affimed N.V. is traded on the NASDAQ under the ticker symbol "AFMD".

  • What is Affimed N.V.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Affimed N.V.?

    Shares of Affimed N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Affimed N.V.'s key executives?

    Affimed N.V.'s management team includes the following people:

    • Dr. Adi Hoess Chief Executive Officer, MD & Member of Management Board(age: 64, pay: $825,050)
    • Dr. Wolfgang Fischer MD, Chief Operating Officer & Member of Management Board(age: 61, pay: $648,730)
    • Dr. Arndt J. G. Schottelius Chief Scientific Officer(age: 59, pay: $592,110)
    • Mr. Angus W. Smith Chief Financial Officer(age: 43, pay: $529,120)
    • Dr. Andreas Harstrick M.D. Chief Medical Officer(age: 64, pay: $461,350)
  • How many employees does Affimed N.V. have?

    As Jul 2024, Affimed N.V. employs 76 workers, which is 65% less then previous quarter.

  • When Affimed N.V. went public?

    Affimed N.V. is publicly traded company for more then 10 years since IPO on 12 Sep 2014.

  • What is Affimed N.V.'s official website?

    The official website for Affimed N.V. is affimed.com.

  • How can i contact Affimed N.V.?

    Affimed N.V. can be reached via phone at +49 6221 674360.

Affimed N.V. company profile:

Affimed N.V.

affimed.com
Exchange:

NASDAQ

Full time employees:

76

Industry:

Biotechnology

Sector:

Healthcare

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Technologiepark
Heidelberg, 69120

CIK: 0001608390
ISIN: NL0015001ZQ0
CUSIP: N01045108